Table 9.6i

Immunosuppression Use for Antirejection Treatment from Transplant

		Year of Transplant
		1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants		4,188	4,516	4,751	4,997	5,195	5,332	5,673	6,170	6,443	6,650
Tx with Antirejection Treatments		1,324	1,184	1,466	1,499	1,417	1,301	1,041	994	1,036	822
Antibodies	Any in Category	12.1%	13.1%	12.5%	14.5%	16.7%	17.5%	17.8%	21.2%	14.9%	15.1%
	Atgam/NRATG/NRATS	1.4%	1.4%	0.7%	0.5%	0.5%	0.6%	0.8%	0.8%	1.1%	0.5%
	OKT3	11.1%	9.7%	6.8%	6.3%	6.7%	5.9%	5.4%	5.7%	4.5%	3.6%
	Thymoglobulin	0.0%	0.3%	1.4%	3.2%	5.2%	5.6%	7.0%	11.3%	7.5%	8.9%
	Zenapax	0.2%	0.9%	1.7%	2.4%	1.6%	1.9%	1.3%	3.4%	0.8%	0.9%
	Simulect	0.1%	1.2%	3.1%	3.1%	4.2%	4.0%	3.0%	0.8%	0.9%	0.6%
	Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	2.0%	1.4%	1.0%	1.3%
Corticosteroids	Any in Category	84.1%	87.3%	89.5%	90.7%	89.1%	90.3%	91.6%	88.5%	91.5%	92.2%
Corticosteroids	Steroids	84.1%	87.3%	89.5%	90.7%	89.1%	90.3%	91.6%	88.5%	91.5%	92.2%
Antimetabolites	Any in Category	0.7%	0.3%	0.2%	0.1%	0.1%	0.0%	0.1%	0.0%	0.3%	0.1%
	Cytoxan	0.7%	0.3%	0.2%	0.1%	0.1%	0.0%	0.1%	0.0%	0.2%	0.1%
	Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%